OBJECTIVE: The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD naïve rheumatoid arthritis patients. METHODS: A Multivariable logistic regression model of rheumatoid arthritis patients starting MTX was developed in a derivation cohort with 285 patients starting MTX in a clinical multicentre, stratified single-blinded trial, performed in seven secondary care clinics and a tertiary care clinic. The model was validated in a validation cohort with 102 patients starting MTX at a tertiary care clinic. Outcome was insufficient response (disease activity score (DAS)28 >3.2) after 3 months of MTX treatment. Clinical characteristics, lifestyle variables, genetic and metabolic biomarkers were determined at baselin...
Objective To identify and validate clinical baseline predictors associated with inadequate response ...
Purpose: Methotrexate (MTX) is the first choice conventional disease-modifying antirheumatic drug (D...
Purpose: Methotrexate (MTX) is the first choice conventional disease-modifying antirheumatic drug (D...
ObjectiveThe objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD ...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
ObjectiveThe objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD ...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
Introduction: Methotrexate (MTX) constitutes the first-line therapy in rheumatoid arthritis (RA), ye...
Introduction: Methotrexate (MTX) constitutes the first-line therapy in rheumatoid arthritis (RA), ye...
Abstract Introduction Methotrexate (MTX) constitutes the first-line therapy in rheumatoid arthritis ...
Objectives: In rheumatology, there is a clinical need to identify patients at high risk (>50%) of...
Objective To identify and validate clinical baseline predictors associated with inadequate response ...
Objective To identify and validate clinical baseline predictors associated with inadequate response ...
Purpose: Methotrexate (MTX) is the first choice conventional disease-modifying antirheumatic drug (D...
Purpose: Methotrexate (MTX) is the first choice conventional disease-modifying antirheumatic drug (D...
ObjectiveThe objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD ...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
ObjectiveThe objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD ...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
Introduction: Methotrexate (MTX) constitutes the first-line therapy in rheumatoid arthritis (RA), ye...
Introduction: Methotrexate (MTX) constitutes the first-line therapy in rheumatoid arthritis (RA), ye...
Abstract Introduction Methotrexate (MTX) constitutes the first-line therapy in rheumatoid arthritis ...
Objectives: In rheumatology, there is a clinical need to identify patients at high risk (>50%) of...
Objective To identify and validate clinical baseline predictors associated with inadequate response ...
Objective To identify and validate clinical baseline predictors associated with inadequate response ...
Purpose: Methotrexate (MTX) is the first choice conventional disease-modifying antirheumatic drug (D...
Purpose: Methotrexate (MTX) is the first choice conventional disease-modifying antirheumatic drug (D...